


04-28-03

RECEIVED

MAY 01 2003

Express Mail No. EL 461 000 129 US

TECH CENTER 1600/2900



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Begovich *et al.*

Confirmation No.: 3564

Serial No.: 09/904,420

Art Unit: 1634

Filed: July 12, 2001

Examiner: C. Myers

For: TCF-1 NUCLEOTIDE SEQUENCE
VARIATIONAttorney Docket No: RPA1003
(1803-300-999)**FEE TRANSMITTAL SHEET**Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The fee required to be filed with the accompanying amendment of even date herewith concerning the above-identified application has been estimated to be \$0.00.


The claim amendment fee has been estimated as shown below:

(Col. 1)0		(Col. 2)		(Col. 3)		<input type="checkbox"/> SMALL ENTITY		<input checked="" type="checkbox"/> OTHER THAN A SMALL ENTITY	
CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID		PRESENT EXTRA	RATE	ADDIT. FEE	OR	RATE	ADDIT. FEE
TOTAL	11	MINUS	20	0	x 9	\$		x 18	\$ 0.00
INDEP.	5	MINUS	7	0	x 42	\$		x 84	\$ 0.00
						\$			\$ 0.00
<input type="checkbox"/> FIRST PRESENTATION OF MULTIPLE DEP. CLAIM					TOTAL	\$	OR	TOTAL	\$ 0.00

Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this sheet is enclosed.

Respectfully submitted,

Date: April 25, 2003


 Rahul Pathak 42,983
 for Nikolaos C. George (Reg. No. 39,201) (Reg. No.)
PENNIE & EDMONDS LLP
 1155 Avenue of the Americas
 New York, New York 10036-2711
 (212) 790-9090

Enclosure



Express Mail No. EL 451 600 129 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Begovich *et al.*

Confirmation No.: 3564

Serial No.: 09/904,420

Art Unit: 1634

Filed: July 12, 2001

Examiner: C. Myers

For: TCF-1 NUCLEOTIDE SEQUENCE
VARIATION

Attorney Docket No: RPA1003
(1803-300-999)

RECEIVED
MAY 01 2003
TECH CENTER 1600/2900

AMENDMENT AND RESPONSE UNDER 37 C.F.R. § 1.116

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Applicants have carefully considered the Office Action mailed February 26, 2003, in connection with the above-captioned patent application. Filed herewith are: 1) Exhibit A ("Marked Up Version of Amended Paragraphs"); 2) Exhibit B (Pending Claims After Entry of the Instant Amendment); and 3) a Fee Transmittal Sheet. This response is being filed within two months from the date of the final Office Action (*see* MPEP § 706.07(f)).

Applicants kindly request reconsideration of the claims in light of the remarks that follow.

IN THE CLAIMS

Please amend the claims as follows:

Please cancel claims 5, 12, 14, 15, 17, and 20-23 without prejudice to renewal.

Please amend claims 18 to read as follows:

18. (Amended) The method of claim 3, wherein said TCF-1 gene comprises SEQ ID NO: 1, an A allele of SEQ ID NO: 1 or the complements thereof.